Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Insufficient chart data. Estimates will improve as the show charts.
- Per-Episode Audience
Est. listeners per new episode within ~30 days
N/A🎙 Daily cadence·397 episodes·Last published yesterday - Monthly Reach
Unique listeners across all episodes (30 days)
N/A - Active Followers
Loyal subscribers who consistently listen
N/A
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 20 epsHosts
Recent guests
Recent episodes
Author Interview: Doctor Chung-Mao Kao, May 2026
Jun 23, 2026
Unknown duration
Discussing PsA: Personalising treatment targets – understanding clinically meaningful improvement
Jun 18, 2026
Unknown duration
EULAR 2026 Review Podcast
Jun 12, 2026
39m 36s
EULAR 2026 Day 4 Highlights Podcast
Jun 6, 2026
4m 50s
EULAR 2026 Day 3 Highlights Podcast
Jun 5, 2026
3m 26s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/23/26 |  Author Interview: Doctor Chung-Mao Kao, May 2026 | Join Professor Peter Nash from the Griffith University in Brisbane, and Doctor Chung-Mao Kao from Taichung Veterans General Hospital, as they discuss the recent publication ‘Malignancy risk in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: A 5-year population-based cohort study’. | — | ||||||
| 6/18/26 |  Discussing PsA: Personalising treatment targets – understanding clinically meaningful improvement | Join Professor Laura Coates and Professor Philip Mease as they discuss a recent publication examining minimal clinically important improvement thresholds in psoriatic arthritis. This month’s conversation explores how patients with differing levels of baseline disease activity may require different degrees of improvement before perceiving treatment benefit, highlighting the potential for more personalised treatment targets and shared decision making in PsA. | — | ||||||
| 6/12/26 |  EULAR 2026 Review Podcast✨ | EULAR conferencerheumatoid arthritis+4 | — | RAPsA+1 | — | EULARrheumatoid arthritis+4 | — | 39m 36s | |
| 6/6/26 |  EULAR 2026 Day 4 Highlights Podcast✨ | Rheumatoid ArthritisPsoriatic Arthritis+4 | — | RA, PsA and axSpA abstracts, posters, and presentations | — | EULAR 2026Rheumatoid Arthritis+4 | — | 4m 50s | |
| 6/5/26 |  EULAR 2026 Day 3 Highlights Podcast✨ | Rheumatoid ArthritisPsoriatic Arthritis+4 | — | RAPsA+1 | — | EULAR 2026Rheumatoid Arthritis+4 | — | 3m 26s | |
| 6/4/26 |  EULAR 2026 Day 2 Highlights Podcast✨ | Rheumatoid ArthritisPsoriatic Arthritis+5 | — | RAPsA+1 | — | EULAR 2026Rheumatoid Arthritis+5 | — | 5m 32s | |
| 6/3/26 |  EULAR 2025 Day 1 Highlights Podcast✨ | Rheumatoid ArthritisPsoriatic Arthritis+4 | — | RA, PsA and axSpA abstracts, posters, and presentations | — | EULAR 2026Rheumatoid Arthritis+4 | — | 5m 37s | |
| 5/28/26 |  Discussing RA: Comparative outcomes with upadacitinib in RA✨ | Rheumatoid Arthritistreatment strategies+3 | — | Mysler et al.Taylor et al.+1 | — | Rheumatoid Arthritisupadacitinib+5 | — | 8m 33s | |
| 5/27/26 |  EULAR 2026 Preview Podcast✨ | EULAR 2026Rheumatoid Arthritis+4 | — | RAPsA+1 | — | EULAR 2026Rheumatoid Arthritis+4 | — | 22m 24s | |
| 5/15/26 |  Discussing axSpA: Biologic therapy outcomes in axial spondyloarthritis✨ | axial spondyloarthritisbiologic therapy+3 | Dr Sofia RamiroProfessor Atul Deodhar | certolizumab pegolsecukinumab+1 | — | axSpAbiologic therapy+6 | — | 21m 55s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 4/30/26 |  Author Interview: Professor Valentino Paci, April 2026✨ | immune-mediated diseasesspondyloarthritis+3 | Professor Valentino Paci | Griffith UniversityDoes Prior Exposure Affect Retention? A Real‑World, Multicentre Assessment of IL‑17 Inhibitor Cycling in Psoriatic Arthritis? | — | immune-mediated diseasesspondyloarthritis+3 | — | 40m 26s | |
| 4/30/26 | Discussing RA: Updated EULAR recommendations and next-step strategies after TNF inhibitor failure✨ | Rheumatoid ArthritisEULAR recommendations+3 | Professor Rieke Alten | The Immune-Mediated Inflammatory Disease ForumEULAR RA management recommendations+2 | — | Rheumatoid ArthritisEULAR+3 | — | 14m 28s | |
| 4/14/26 |  Discussing PsA: Bimekizumab in PsA: Clinical efficacy and updated safety profile✨ | PsAbimekizumab+4 | Phillip Mease | bimekizumabPsA | — | PsAbimekizumab+4 | — | 16m 32s | |
| 4/9/26 | Author Interview: Professor Helena Marzo-Ortega, March 2026✨ | psoriatic arthritisclinical discussion+3 | Professor Helena Marzo-Ortega | Griffith UniversityLeeds Teaching Hospitals NHS Trust+1 | — | psoriatic arthritisEULAR+3 | — | 37m 39s | |
| 3/26/26 | Discussing RA: Malignancy risk in patients with RA and the evolution of JAKi prescriptions✨ | rheumatoid arthritismalignancy risk+4 | — | b/tsDMARDSJAKi+2 | — | rheumatoid arthritismalignancy risk+4 | — | 10m 02s | |
| 3/19/26 | Discussing axSpA: Symptom duration impact on bimekizumab efficacy and therapeutic switching drivers✨ | axSpAbimekizumab+3 | Dr Sofia RamiroDr Atul Dheodhar | bimekizumabaxSpA+1 | — | axSpAbimekizumab+3 | — | 33m 29s | |
| 3/12/26 | Author Interview: Doctor Carlo Tur, February 2026✨ | B-cell depletionrheumatology+3 | Doctor Carlo Tur | Griffith UniversityFriedrich-Alexander-University+1 | BrisbaneErlangen-Nurnberg | B-cell depletionrheumatology+5 | — | 29m 35s | |
| 3/5/26 | Author Interview - Professor Andrew Cope, 2026✨ | rheumatoid arthritisclinical trials+3 | Professor Andrew Cope | Griffith UniversityCentre for Rheumatic Diseases+2 | — | rheumatoid arthritisabatacept+3 | — | 24m 50s | |
| 2/27/26 | Discussing RA: Pain outcomes and drug effectiveness of JAK inhibitors in RA and PsA✨ | Rheumatoid ArthritisPsoriatic Arthritis+3 | — | UPAADA+5 | RAPsA | Rheumatoid ArthritisPsoriatic Arthritis+3 | — | 8m 38s | |
| 2/13/26 | Discussing PsA: Risankizumab efficacy across machine learning defined and complex PsA phenotypes✨ | PsAmachine learning+3 | Phillip Mease | GRAPPAPsA | — | PsArisankizumab+5 | — | 20m 50s | |
| 2/3/26 | Author Interview: Professor Matthew Brown, 2026✨ | uveitisaxial spondyloarthritis+4 | Professor Matthew Brown | Genomics EnglandLow uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: Pooled results from Phase 2b/3 trials | Griffith UniversityBrisbane | uveitisaxial spondyloarthritis+5 | — | 18m 29s | |
| 1/29/26 | Discussing RA: Long-term effectiveness and sex differences of JAK inhibitors in rheumatoid arthritis✨ | rheumatoid arthritisJAK inhibitors+4 | — | TOFbaricitinib+3 | RA | rheumatoid arthritisJAK inhibitors+6 | — | 9m 20s | |
| 12/18/25 | Discussing RA: UPA outcomes and the impact of GCs on targeted therapies in RA | Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he and Doctor Reike Alten will be reviewing two papers. The first paper by Kameda et al. assessed long-term safety and efficacy of UPA over 5 years in Japanese patients with moderate-to- severe active RA and an inadequate response to stable doses of csDMARDs-IR. The second paper by Salvato et al. assessed the impact of chronic oral low-dose GCs on the efficacy and retention rates of JAK inhibitors compared to other mechanisms of action therapies in a cohort of RA patients with inadequate response to TNFi. | — | ||||||
| 12/11/25 | Discussing axSpA: Real-world outcomes for patients with axSpA receiving SC infliximab | Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered a retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab | — | ||||||
| 12/4/25 | Discussing PsA: Uveitis risk and treatment sequencing outcomes in axSpa and PsA | Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the effectiveness and safety of upadacitinib with secukinumab and adalimumab’ and ‘the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA’. | — | ||||||
Showing 25 of 361
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.